To investigate the phylogenetic and therapeutic implications of the genetic divergence in the dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) genes among different Pneumocystis carinii strains, these 2 genes in P. carinii obtained from 7 different host species were sequenced. Pairwise comparison of the DHPS sequences demonstrated 6%-24% and 6%-30% divergence in the nucleotide and deduced amino acid sequences, respectively. The DHFR gene was even more divergent, with differences of 15%-34% and 18%-42% in the nucleotide and deduced amino acid sequences, respectively. Phylogenetic analysis of DHFR and DHPS sequences revealed that all P. carinii strains were confined within a distinct group that was closely related to ascomycete fungi and that human-derived P. carinii was most closely related to monkey-derived P. carinii. Recognizing the substantial differences in the DHFR and DHPS genes among P. carinii from different host species has important implications for drug discovery and the development of new diagnostic methods.
obtained by investigation of P. carinii organisms from murine models. Recent studies clearly show substantial differences in the primary sequences of these 2 enzymes between human-and murine-derived P. carinii [1, 2] . It is unknown how these differences influence the therapeutic success of drugs that are evaluated in animals but will ultimately be used in humans.
It is widely accepted, primarily on the basis of molecular data, that P. carinii is a member of the fungal kingdom [3] . However, its precise taxonomic position within this group remains controversial-with assignment to the ascomycete fungi or to the basidiomycetous red yeasts. Recently, Baldauf et al. [4] created a phylogenetic tree for eukaryotes, based on the sequences of 4 of the taxonomically most broadly sampled proteins, and placed P. carinii among the Ascomycota.
Our primary goal was to determine the sequences of the DHFR and DHPS genes in P. carinii isolated from different host species. Through sequence analysis of these 2 genes, we examined the phylogenetic relationship among different P. carinii strains and looked for potential significance of the differences in the primary sequences of DHFR and DHPS for drug development.
Materials and Methods
P. carinii isolates from mouse, rat, ferret, owl monkey (Aotus nancymai), dog, and rabbit were obtained from the National Institutes of Health (Bethesda, MD), Indiana University (Indianapolis), University of Rochester School of Medicine (Rochester, [1] .
To amplify the DHFR and DHPS genes by polymerase chain reaction (PCR), we used primers FR01, FR634, PK160, and PSB1, as described elsewhere [1] , and newly synthesized primers as follows: FR01h, 5 -ATGGATTGGCAAAAGTCATTGAC-3 ; FR153, 5 -C-AGGAAACAGCTATGACGATGAATGTTGTTTTGATGGG-3 ; FR428, 5 -GTAAAACGACGGCCAGCTGTGCACCACCTATAA-C-3 ; FR633, 5 -GTAAAACGACGGCCAGTTCATTTATTTTACC-ATGAGGAA-3 ; PS22, 5 -CAGGAAACAGCTATGACCTACAC-ATATTATGGC-3 ; PS831, 5 -GTAAAACGACGGCCAGAAC-TTCTTTCCAAATAGCATC-3 . The last 5 primers contained the sequence of universal M13 reverse (boldface type) or M13 forward (italic type) primer, to facilitate sequencing. The DHFR genes from rat-, mouse-, and rabbit-derived P. carinii were amplified with primers FR01-FR634. The DHFR genes from dog-and ferret-derived P. carinii were amplified in 2 overlapping fragments with primers FR01-FR428 and FR153-FR633, respectively. The DHPS genes from rabbit-and ferret-derived P. carinii were amplified with primers PK160-PSB1. The DHPS gene from dog-derived P. carinii was amplified in 2 overlapping fragments with primers PK160-PSB1 and PS22-PS831, respectively.
PCR amplification was performed with a combination of hot-start and touchdown protocols, as described elsewhere [1] . The PCR products were sequenced either directly or after subcloning [1] . Sequence analysis was performed by use of MacVector 6.5.3 (Oxford Molecular). Phylogenetic trees were constructed by use of PHYLIP software (version 3.573c; University of Washington) and the neighborjoining method. Sequence alignments are available on request. GenBank accession numbers of the sequences obtained in this study are AF175561, AF186097, AY017418, and AF322061-6.
Results

P. carinii DHFR gene sequences.
The full-length sequences of the rat-and human-derived P. carinii DHFR genes have been reported elsewhere [1, 5] . In the present study, we determined a portion of the DHFR gene in P. carinii isolated from rat, mouse, ferret, rabbit, dog, and monkey. Only 1 isolate was obtained from each species, except for rat and mouse, from which 2 isolates were obtained. No sequence variation was seen in the 2 isolates from mouse or rat. The sequence of the ratderived P. carinii DHFR gene determined in this study was identical to the published sequence [5] , except for an insertion of a C in the intron. Alignment of the DHFR sequences from 7 P. carinii strains showed substantial differences in both the nucleotide and deduced amino acid sequences. In pairwise comparison (table 1), the highest degree of divergence was seen between rat-and monkey-derived P. carinii (34% difference in the nucleotide sequence) or between rat-and human-derived P. carinii (42% difference in the amino acid sequence). The lowest degree of divergence was seen between mouse-and ratderived P. carinii, with 15% and 18% differences in the nucleotide and deduced amino acid sequences, respectively. The human-derived P. carinii DHFR was most closely related to the monkey-derived P. carinii DHFR.
The introns in the DHFR genes from different P. carinii strains were identical in location but varied in size and sequence. The size varied from 42 bp in the human strain to 49 bp in the dog strain. Strikingly, the intron sequences exhibited a very high degree of divergence, ranging from 20% between rat and mouse strains to 60% between dog and rabbit strains in the overlapping regions.
P. carinii DHPS gene sequences. The full-length sequences of the rat-, mouse-, and human-derived P. carinii DHPS genes have been reported elsewhere [1, 2, 6] . A portion of the monkeyderived P. carinii DHPS gene sequence also has been published elsewhere [7] . In this study, we determined a portion of the DHPS gene in P. carinii isolates from ferret, rabbit, and dog (1 isolate each). Alignment of these 7 sequences showed fewer differences than for the DHFR gene. By pairwise comparison (table 1), the highest degree of divergence was seen between ferret-and monkey-derived P. carinii, with 24% and 30% differences in the nucleotide and deduced amino acid sequences, respectively. The lowest degree of divergence was seen between mouse-and ratderived P. carinii, with 6% difference in both the nucleotide and deduced amino acid sequences. The human-derived P. carinii DHPS was most closely related to the monkey-derived P. carinii DHPS, which is similar to the findings observed with the DHFR genes.
Phylogenetic analysis. To examine the evolutionary relationships among members of the Pneumocystis genus and between P. carinii and other organisms, phylogenetic trees were constructed on the basis of the DHFR and DHPS protein sequences (figure 1). Both trees showed that all P. carinii strains were well confined within a distinct group (bootstrap value of Figure 1 . Phylogenetic trees of Pneumocystis carinii and other organisms based on deduced amino acid sequences of dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) genes. Both trees were constructed by use of the neighbor-joining method and were rooted by using midpoint rooting. Bootstrap values are indicated at nodes and represent percentage of 1000 bootstrap replicates that support the branching order; only bootstrap values 140% are shown. Branch lengths are proportional to amount of amino acid change along branches. Colors identify different phyla of organisms. GenBank accession numbers for these sequences are as follows: human-derived P. carinii, AF090368 for DHFR and AF139132 for DHPS; rat-derived P. carinii, M26495 for DHFR and M86602 for DHPS; mouse-derived P. carinii, U66283 for DHPS; Schizosaccharomyces pombe, L13703 for DHFR and AL031854 for DHPS; Saccharomyces cerevisiae, Y00887 for DHFR and X96722 for DHPS; Candida albicans, X78968 for DHFR; Cryptococcus neoformans, S58802 for DHFR; Neurospora crassa, AL355929 for DHPS; Bucillus subtilis, M20012 for DHFR and Z99104 for DHPS; Neisseria meningitidis, X68067 for DHFR; Streptococcus pneumoniae, Z74778 for DHFR and U16156 for DHPS; Escherichia coli, J01609 for DHFR and L06494 for DHPS; Lactobacillus casei, M10922 for DHFR; Mycobacterium tuberculosis, Z95557 for DHPS; Mycobacterium leprae, AF117618 for DHPS; Leishmania major, X51733 for DHFR; Trypanosoma cruzi, L22484 for DHFR; Toxoplasma gondii, L08489 for DHFR and U61852 for DHPS; Plasmodium falciparum, J03772 for DHFR and Z30665 for DHPS. The remaining accession numbers are listed in Materials and Methods. 100%) that was closely related to other fungi: Schizosaccharomyces pombe or Neurospora crassa were the closest relatives among the selected organisms. In both trees, human-and monkey-derived P. carinii were placed in a subgroup, as were ratand mouse-derived P. carinii.
Discussion
Our findings show that the DHFR and DHPS genes of P. carinii isolated from different host species differ substantially from each other in both nucleotide and amino acid sequences. These results are consistent with prior observations that P. carinii organisms are host-species specific. Our phylogenetic analysis of P. carinii DHFR and DHPS genes provides further evidence for the classification of this organism as a fungus [3] . The finding of a close association of P. carinii with S. pombe and N. crassa supports the concept that P. carinii is an Ascomycota [4] . Nevertheless, additional sequence data from other fungi are needed to more precisely determine the taxonomic position of P. carinii within the fungal kingdom.
Recognizing and understanding the substantial differences in the primary sequences of the DHFR and DHPS enzymes has important implications for the development of new inhibitors against these 2 enzymes for use as therapeutic agents for human PCP. In studies of other organisms, DHFRs from different species were very poorly conserved in the primary sequences and exhibited considerable species-to-species variability in sensitivity toward various inhibitors. Identification of therapeutic agents against P. carinii DHFR is dependent largely on studies of rat-derived organisms and has been quite successful to date. However, we found that the human-derived P. carinii DHFR differs from rat-derived P. carinii DHFR by 38% (79/206) in amino acid sequence. A sequence alignment of DHFRs from P. carinii and other organisms [8] indicates 3 interesting amino acid changes in the highly conserved regions between rat-and human-derived P. carinii: Glu-32, Ile-65, and Thr-81 in the ratderived strain are changed to Asp-32, Leu-65, and Ser-81, respectively, in the human-derived strain. On the basis of the crystal structures of DHFRs from Escherichia coli and human and rat-derived P. carinii, these 3 residues are located in the active sites of the enzymes [8, 9] .
The amino acid change at position 32 in P. carinii DHFR is of particular interest, because it is involved in binding to substrates and inhibitors, as shown by structural studies of other DHFRs [8, 9] . In P. carinii DHFR, the amino acid residue at position 32 corresponds to Glu-30 in human DHFR and Asp-27 in E. coli DHFR. In fact, Glu-30 is rigorously conserved in all known vertebrate DHFRs, whereas Asp-27 is highly conserved in all bacterial and protozoan DHFRs [9] . Studies of human and mouse DHFR variants with 30 GlurAsp have found remarkable changes in the rate of folate reduction and hydride transfer [9] . Although our preliminary kinetic studies of the recombinant human-derived P. carinii DHFR have not found any significant differences in K m values for substrates and K i values for a few selected inhibitors, compared with the rat-derived P. carinii DHFR [10] , this observation suggests that it is worth studying the kinetic behavior of these 2 enzymes in more detail by using additional inhibitors. Determining the effects of the different primary sequences on the three-dimensional structures of the enzymes and on the interactions with potential substrates or inhibitors may facilitate development of novel inhibitors.
There is no direct proof that P. carinii DHPS mutations are responsible for clinical sulfa resistance. However, sequence analysis of the DHPS genes from different host-derived P. carinii provides further support for prior observations that DHPS mutations in the human-derived P. carinii DHPS gene are associated with sulfa exposure and possible resistance [1, 2, 11] . On the basis of sequence alignment of the DHPS proteins from P. carinii and other organisms, the mutations (55 ThrrAla and 57 ProrSer) in human-derived P. carinii DHPS are located in a highly conserved region that is characterized by the sequence Thr-Arg-Pro (identical among all the P. carinii strains and other organisms shown, except for ferret-and monkey-derived P. carinii and Plasmodium falciparum, in which the sequences are SerArg-Pro, Thr-Gly-Pro, and Ser-Ala-Pro, respectively). The presence of mutations in this highly conserved region suggests that these mutations are not random occurrences but rather are the result of selective drug pressure. According to the crystal structure of the E. coli DHPS, the analogous 3 residues (codons 62-64 in E. coli) are involved in binding to the substrate and sulfa drugs [12] . Mutations at these positions confer sulfa resistance in organisms such as P. falciparum [13] and E. coli [14] .
Genetic divergence among P. carinii organisms also has implications for the development of molecular techniques for diagnosing human PCP. Although primers based on the rat-derived P. carinii DHFR gene have been reported to be useful in detecting P. carinii in clinical samples [15] , we and others have shown that these primers do not amplify the DHFR gene of human-derived P. carinii because of considerable mismatches between the primers and the human-derived P. carinii DHFR gene [1] . This experience suggests that it is important, given the substantial divergence among different P. carinii strains, to verify the identity of the amplified product by sequencing when using primers or probes from one strain for detection of another strain. Thus, understanding the genetic divergence among different P. carinii strains has important implications for drug discovery and the development of new diagnostic methods. Rational design of potent inhibitors of therapeutic targets of human P. carinii should be based on the enzymes from humanderived organisms.
